04-1571-I
Anti-RNA polymerase II subunit B1 (phospho CTD Ser-2), clone 3E10 (rat monoclonal).
culture supernatant, clone 3E10, from rat
Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
DNA-directed RNA polymerase II subunit RPB1, RNA polymerase II subunit B1, DNA-directed RNA polymerase II subunit A, DNA-directed RNA polymerase III largest subunit, RNA-directed RNA polymerase II subunit RPB1
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
rat
Quality Level
antibody form
culture supernatant
antibody product type
primary antibodies
clone
3E10, monoclonal
species reactivity
mouse
species reactivity (predicted by homology)
human (immunogen homology)
technique(s)
ChIP: suitable
ELISA: suitable
western blot: suitable
isotype
IgG1κ
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
phosphorylation (pSer2)
Gene Information
human ... POLR2B(5431)
General description
RPB1 (RNA polymerase II subunit B1) is the catalytic component of RNA polymerase II which synthesizes mRNA and non-coding RNAs. During transcription, elongation is influenced by the phosphorylation status of the C-terminal domain (CTD) of RPB1, which acts as an assembly platform for factors regulating transcription initiation, elongation, termination and mRNA processing. Phosphorylation occurs mainly at residues ′Ser-2′ and ′Ser-5′ of the tandem 7 residue repeats in the C-terminal domain (CTD), which activates Pol II. This phosphorylation also can occur at ′Ser-7′ of the heptapepdtide repeat. This antibody recognizes the ′Ser-2′ CTD residue of RPB1.
Specificity
Demonstrated to react with human RBP1 in Ni et al., 2011. Transcription 2:5, 237-242
This antibody recognizes RNA Polymerase II subunit B1 phosphorylated at Ser2 of the C-terminal domain (CTD).
Immunogen
Epitope: Phosphorylated Ser2 at the C-terminal domain (CTD)
Ovalbumin-conjugated linear peptide corresponding to human RNA Polymerase II subunit B1 phosphorylated at Ser2 of the C-terminal domain (CTD).
Application
Anti-RNA polymerase II subunit B1 (phospho CTD Ser-2), clone 3E1 (rat monoclonal) is a highly specific rat monoclonal antibody & that targets RNA Polymerase & has been tested in western blotting.
Chromatin Immunoprecipitation Analysis: A representative lot was used by an independent laboratory to immunoprecipitate RNA polymerase II subunit B1 (phospho-CTD Ser-5) in ChIP (Chapman, R., et al. (2007). Science. 318(5857):1780 -1782.).
Demonstrated to react with human RBP1 in Ni et al., 2011. Transcription 2:5, 237-242
Demonstrated to react with human RBP1 in Ni et al., 2011. Transcription 2:5, 237-242
Research Category
Epigenetics & Nuclear Function
Epigenetics & Nuclear Function
Research Sub Category
Transcription Factors
Transcription Factors
Quality
Evaluated by Western Blotting in untreated and lambda phosphatase treated NIH/3T3 cell lysate.
Western Blotting Analysis: A 1:2,000 dilution of this antibody detected RNA Polymerase II subunit B1 (phospho CTD Ser-2) in untreated NIH/3T3 cell lysate.
Western Blotting Analysis: A 1:2,000 dilution of this antibody detected RNA Polymerase II subunit B1 (phospho CTD Ser-2) in untreated NIH/3T3 cell lysate.
Target description
~220 kDa observed
Linkage
Replaces: 04-1571
Physical form
Unpurified
Unpurified rat monoclonal IgG1κ tissue culture supenatant with 0.05% sodium azide.
Storage and Stability
Stable for 1 year at -20°C from date of receipt.
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Analysis Note
Control
Untreated and lambda phosphatase treated NIH/3T3 cell lysate
Untreated and lambda phosphatase treated NIH/3T3 cell lysate
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
WGK
WGK 1
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
In vivo live imaging of RNA polymerase II transcription factories in primary cells.
Ghamari, Alireza, et al.
Genes & Development, 27, 767-777 (2013)
Dan Yu et al.
Nucleic acids research, 47(9), 4462-4475 (2019-03-14)
The general transcription factor P-TEFb, a master regulator of RNA polymerase (Pol) II elongation, phosphorylates the C-terminal domain (CTD) of Pol II and negative elongation factors to release Pol II from promoter-proximal pausing. We show here that P-TEFb surprisingly inhibits
Zhaoqing Zheng et al.
eLife, 6 (2017-06-09)
MECP2 mutations underlying Rett syndrome cause widespread misregulation of gene expression. Functions for MeCP2 other than transcriptional are not well understood. In an ex vivo brain preparation from the pond turtle Trachemys scripta elegans, an intraexonic splicing event in the
Xiaohong Zhao et al.
Cell reports, 34(11), 108870-108870 (2021-03-18)
Ibrutinib, a bruton's tyrosine kinase (BTK) inhibitor, provokes robust clinical responses in aggressive mantle cell lymphoma (MCL), yet many patients relapse with lethal Ibrutinib-resistant (IR) disease. Here, using genomic, chemical proteomic, and drug screen profiling, we report that enhancer remodeling-mediated
Jing Gao et al.
Haematologica (2021-06-25)
Despite significant progress in the treatment of patients with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), prognosis of patients with relapsed disease remains poor due to the emergence of drug resistance and subsequent disease progression. Identification of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service